Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

NCT07392892 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07392892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07392892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 14, 2026
Completion date
July 21, 2032
Enrollment
840 (estimated)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastroesophageal junction cancer, metastatic gastric cancer, untreated advanced or metastatic gastric, gastroesophageal junction , or esophageal adenocarcinoma